Sofinnova Capital XI will back a new generation of pioneering biopharmaceutical and medical technology companies addressing urgent unmet clinical needs, states Sofinnova.

Sofinnova Capital XI attracted strong support from a global base of blue-chip institutional investors – among them sovereign wealth funds, leading pharmaceutical companies and other corporates, as well as insurance companies, foundations, and family offices, states Sofinnova further. Commitments came from across Europe, North America, Asia, and the Middle East, with a majority of returning LPs and a significant number of new top-tier investors.

“This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach. We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide,” says Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners. “Achieving this milestone in today’s volatile fundraising environment speaks to the strength of our model and the confidence our investors continue to place in us.”

Related article

Lars Ekman: Running R&D on both sides of the Atlantic

Lars Ekman from Gothenburg, Sweden, has more than 30 years experience in senior executive, scientific, and clinical functions within life sciences across the globe. He is today capitalizing on his extensive knowledge and sharing his experience as Executive Partner at Sofinnova Investments in the USA. Lars Ekman’s career path has taken him from Sweden to […]

Sofinnova Capital XI is actively deploying capital, with investments already made in a few portfolio companies. The fund will continue to support early-stage biotech and medtech ventures across Europe and North America, participating in both initial and follow-on rounds.